Showing posts with label Memorial Sloan Kettering. Show all posts
Showing posts with label Memorial Sloan Kettering. Show all posts

Thursday, December 31, 2015

Memorial Sloan Kettering Masterminds the Future of Patient-Focused Care

NYC's Memorial Sloan Kettering Cancer Center will open its outpatient surgery center in January.
Image: Unsplash.com
Nobody likes going to the hospital—especially when it’s for something big and scary, like cancer. Sanitary white walls, humming machinery, woozy patients and worried family members—no thanks! But one hospital is aiming to make your visit quicker, friendlier, and more comfortable even if you’re suffering from a serious illness.

The Memorial Sloan Kettering Cancer Center in Manhattan’s Upper East Side will open its $200 million new outpatient surgery center this January. With the latest technology, room for future innovations, and a gorgeous design by Perkins Eastman and ICRAVE, the Josie Robertson Surgery Center will completely redefine what it means to go to the hospital.

Thanks to an active board including Bill E Ford (General Atlantic), James Robinson (RRE Ventures LLC), and Charles Sawyers (The Column Group LLC), the new Surgery Center will not only look great; it will comfort both patients and their families, as well as making use of the cutting edge of healthcare technology (think robots in surgery and iPads available for patient use!).

One big technological win is that patients will receive plastic tracking badges as soon as they arrive. These badges will collect data about how much the patients can move around after surgery and how well they’re recovering. That’s good not just for the patient and their doctor, but also for useful insight into future patient needs.

As for patients’ families, they’ll have plenty of support as well, including mobile device charging stations and an Xbox nook for fitness activities in the waiting room. The building design, inspired by hotel lobbies and co-working spaces, will put them at ease during a stressful time.

And we’re talking serious surgery here—say, a double mastectomy and breast reconstruction—performed with state-of-the-art equipment and in a healthy, soothing environment that gets patients in and out within a day.

JRSC exists partly because Memorial Sloan Kettering’s main campus is running out of room. But it’s also meant to be a place where medical staff can innovate and really serve their patients face-to-face and in a personal way.

“There’s nothing else like this that I’ve ever heard of,” said Brett Simon, and anesthesiologist and the JRSC’s director. He also pointed out his team’s dedication to meaningful patient interaction and support: “While it might not be that hard, medically, to get someone out the door, having them emotionally and spiritually happy and feeling supported is really a big deal.”

Friday, November 14, 2014

Memorial Sloan Kettering Creates a Way to Treat Gastrointestinal Infections

Memorial Sloan Kettering research, aided by a donation from the Marie and Henry R. Kravis Foundation, may help prevent C.diff infections
New research from Memorial Sloan Kettering
may help prevent C.diff infections.
Image: Memorial Sloan Kettering
Anyone who has ever suffered from a gastrointestinal infection, commonly referred to as a stomach flu or viral gastroenteritis, knows that they are incredibly uncomfortable and in some instances, deadly. C.diff, or Clostridium difficile, is a bacterial pathogen that releases toxins into the body that damages the lining of the large intestine. This leads to severe abdominal pain that can even lead to a much more serious condition that can take weeks or months to resolve. In rare cases, the ailment can even be fatal.

According to the Mayo Clinic, for many years there has been no effective treatment for gastrointestinal inflections. However, new research from Memorial Sloan Kettering is creating a different strategy that looks to use a bacterial species that is found in healthy gastrointestinal tracts to prevent C.diff infections.

Eric Pamer, the Head of the Division of General Medicine and Chief of MSK’s Infectious Diseases Service, stated, “It’s been well appreciated that the loss of normal bacteria in the intestines can lead to infection with C. diff. Now that we know which bacterial species has a protective effect, we can begin to look for ways to develop a clinical treatment,” of advancements being made.

Researchers have known for years that treatment with antibiotics can damage bacterial strains that are beneficial in the intestines and thus allow C.diff to continue growing and damage the body. Recent studies have shown that fecal transplants—where uninfected feces are transplanted to the colon of someone with C.diff.—can lead to a suppression of C.diff infections.

The research conducted at Memorial Sloan Kettering was aided by a generous gift of $100 million from the Marie-Josée and Henry R. Kravis Foundation, which sought to bring financial aid to cancer biology, bioinformatics, pathology and systems biology. The Marie-Josée and Henry R. Kravis Center for Molecular Oncology (CMO) undertook an endeavor to help with the research of cancer through genomic analysis of patient-derived tumors. It’s due to such contributions that Memorial Sloan Kettering aims to reach the ambitious goal of expediting and streamlining cancer genomics research to guide cancer treatments, and is what makes it a leader in other health research fields.

For further reading about the new gastrointestinal treatment research, MSK’s Eric Pamer is also a senior author of a study on the subject of C.diff, which can be found published in Nature: International weekly journal of science.
Google